Oxygenta [OXYGENTAPH] vs Sun Pharmaceutical [SUNPHARMA] Detailed Stock Comparison
Oxygenta
BSE
Loading...
Sun Pharmaceutical
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Oxygenta wins in 6 metrics, Sun Pharmaceutical wins in 12 metrics, with 0 ties. Sun Pharmaceutical appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Oxygenta | Sun Pharmaceutical | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 444.32 | 37.73 | Sun Pharmaceutical |
| Price-to-Book Ratio | -10.31 | 5.42 | Oxygenta |
| Debt-to-Equity Ratio | -2.49 | 3.26 | Oxygenta |
| PEG Ratio | 1.38 | -1.94 | Sun Pharmaceutical |
| EV/EBITDA | -24.19 | 23.98 | Oxygenta |
| Profit Margin (TTM) | -13.45% | 19.29% | Sun Pharmaceutical |
| Operating Margin (TTM) | -50.72% | 24.34% | Sun Pharmaceutical |
| EBITDA Margin (TTM) | N/A | 24.34% | N/A |
| Return on Equity | 38.69% | 15.08% | Oxygenta |
| Return on Assets (TTM) | -11.61% | 11.87% | Sun Pharmaceutical |
| Free Cash Flow (TTM) | $-87.89M | $119.44B | Sun Pharmaceutical |
| Dividend Yield | N/A | 1.26% | N/A |
| 1-Year Return | -20.28% | -13.00% | Sun Pharmaceutical |
| Price-to-Sales Ratio (TTM) | 2.22 | 7.28 | Oxygenta |
| Enterprise Value | $3.17B | $3,678.87B | Sun Pharmaceutical |
| EV/Revenue Ratio | 2.84 | 6.84 | Oxygenta |
| Gross Profit Margin (TTM) | -24.33% | 79.58% | Sun Pharmaceutical |
| Revenue per Share (TTM) | $31 | $224 | Sun Pharmaceutical |
| Earnings per Share (Diluted) | $-3.95 | $43.23 | Sun Pharmaceutical |
| Beta (Stock Volatility) | 0.42 | 0.28 | Sun Pharmaceutical |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Oxygenta vs Sun Pharmaceutical Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Oxygenta | 1.06% | 1.69% | -4.31% | -39.94% | -9.48% | -18.70% |
| Sun Pharmaceutical | 1.44% | 4.12% | 4.66% | -1.50% | -0.70% | -12.45% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Oxygenta | -20.28% | 144.99% | 530.20% | 969.02% | 609.78% | 191.63% |
| Sun Pharmaceutical | -13.00% | 69.49% | 239.84% | 85.82% | 711.29% | 2,598.03% |
News Based Sentiment: Oxygenta vs Sun Pharmaceutical
Oxygenta
News based Sentiment: NEGATIVE
September brought concerning financial results for Oxygenta Pharmaceutical, with a substantial increase in net loss and a declining share price. While the AGM took place, the underlying financial challenges and mixed investor signals create a negative outlook for the month, making it a significant period for investors to reassess their positions.
Sun Pharmaceutical
News based Sentiment: MIXED
October was a month of significant contrasts for Sun Pharma. While the company demonstrated revenue growth and made strategic acquisitions, the imposition of a 100% US tariff on Indian pharmaceuticals presents a major headwind. This combination of positive and negative developments creates a mixed investment outlook.
Performance & Financial Health Analysis: Oxygenta vs Sun Pharmaceutical
| Metric | OXYGENTAPH | SUNPHARMA |
|---|---|---|
| Market Information | ||
| Market Cap | ₹2.61B | ₹4.01T |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 6,823 | 3,168,435 |
| 90 Day Avg. Volume | 7,182 | 2,778,768 |
| Last Close | ₹69.70 | ₹1,654.70 |
| 52 Week Range | ₹67.00 - ₹133.50 | ₹1,548.00 - ₹1,947.00 |
| % from 52W High | -47.79% | -15.01% |
| All-Time High | ₹133.50 (Jun 09, 2025) | ₹1,960.35 (Sep 30, 2024) |
| % from All-Time High | -47.79% | -15.59% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.20% | 0.10% |
| Quarterly Earnings Growth | N/A | -0.20% |
| Financial Health | ||
| Profit Margin (TTM) | -0.13% | 0.19% |
| Operating Margin (TTM) | -0.51% | 0.24% |
| Return on Equity (TTM) | 0.39% | 0.15% |
| Debt to Equity (MRQ) | -2.49 | 3.26 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹-7.15 | ₹300.99 |
| Cash per Share (MRQ) | ₹0.03 | ₹108.88 |
| Operating Cash Flow (TTM) | ₹-61,057,000 | ₹110.84B |
| Levered Free Cash Flow (TTM) | ₹-96,826,000 | ₹109.29B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.26% |
| Last 12-Month Dividend | N/A | ₹21.00 |
Valuation & Enterprise Metrics Analysis: Oxygenta vs Sun Pharmaceutical
| Metric | OXYGENTAPH | SUNPHARMA |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 444.32 | 37.73 |
| Forward P/E | N/A | 49.91 |
| PEG Ratio | 1.38 | -1.94 |
| Price to Sales (TTM) | 2.22 | 7.28 |
| Price to Book (MRQ) | -10.31 | 5.42 |
| Market Capitalization | ||
| Market Capitalization | ₹2.61B | ₹4.01T |
| Enterprise Value | ₹3.17B | ₹3.68T |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.84 | 6.84 |
| Enterprise to EBITDA | -24.19 | 23.98 |
| Risk & Other Metrics | ||
| Beta | 0.42 | 0.28 |
| Book Value per Share (MRQ) | ₹-7.15 | ₹300.99 |
Financial Statements Comparison: Oxygenta vs Sun Pharmaceutical
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | OXYGENTAPH | SUNPHARMA |
|---|---|---|
| Revenue/Sales | ₹151.35M | ₹137.86B |
| Cost of Goods Sold | ₹188.17M | ₹28.15B |
| Gross Profit | ₹-36.83M | ₹109.71B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹-76.77M | ₹33.72B |
| EBITDA | ₹-66.61M | ₹47.66B |
| Pre-Tax Income | ₹-81.48M | ₹31.73B |
| Income Tax | ₹-20.42M | ₹8.70B |
| Net Income (Profit) | ₹-61.06M | ₹22.93B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | OXYGENTAPH | SUNPHARMA |
|---|---|---|
| Cash & Equivalents | ₹17,000 | ₹102.69B |
| Total Current Assets | ₹309.43M | ₹526.24B |
| Total Current Liabilities | ₹858.47M | ₹181.94B |
| Long-Term Debt | ₹215.22M | ₹3.58B |
| Total Shareholders Equity | ₹-250.25M | ₹724.86B |
| Retained Earnings | ₹-735.63M | ₹578.62B |
| Property, Plant & Equipment | ₹14.36M | ₹100.36B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | OXYGENTAPH | SUNPHARMA |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | OXYGENTAPH | SUNPHARMA |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 6,823 | 3,168,435 |
| Average Daily Volume (90 Day) | 7,182 | 2,778,768 |
| Shares Outstanding | 36.98M | 2.40B |
| Float Shares | 3.88M | 1.06B |
| % Held by Insiders | 0.80% | 0.56% |
| % Held by Institutions | 0.00% | 0.25% |
Dividend Analysis & Yield Comparison: Oxygenta vs Sun Pharmaceutical
| Metric | OXYGENTAPH | SUNPHARMA |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹21.00 |
| Last 12-Month Dividend Yield | N/A | 1.26% |
| 3-Year Avg Annual Dividend | N/A | ₹14.67 |
| 3-Year Avg Dividend Yield | N/A | 0.46% |
| 3-Year Total Dividends | N/A | ₹44.00 |
| Ex-Dividend Date | N/A | Jul 07, 2025 |